Q-omics provides the consensus-scored CAMTA2 profile across patient tissues and cancer cell-line models. CAMTA2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CAMTA2 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CAMTA2 RNA expression shows 19,795 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where CAMTA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAMTA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAMTA2 survival associations across molecular data types. CAMTA2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAMTA2 RNA expression–survival associations across cancer types. High CAMTA2 expression shows unfavorable associations in ACC, LUSC and KICH, but favorable associations in PAAD, BRCA and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CAMTA2 RNA expression.
This table summarizes CAMTA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CAMTA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAMTA2 shows lower tumor expression in BLCA, COAD, KICH, READ and LUSC and higher tumor expression in LIHC. The BLCA box plot shows higher CAMTA2 RNA expression in normal versus tumor tissue (log2 FC = −1.214, t-test p < 0.001).
This table shows molecular features associated with CAMTA2 in patient tissues and cancer cell lines. In patient samples, CAMTA2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CAMTA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
